Description
Alere 425-080 - ALERE I FLU A&B CONTROL
Alere i Influenza A & B Molecular results in less than 15 minutes
The ID NOW Influenza A & B 2 assay delivers molecular flu results in 13 minutes or less on our unique ID NOW platform; making it significantly faster than other molecular methods and more accurate than conventional rapid tests. Rapid diagnostic tests with increased sensitivity are essential for the reliable detection of influenza A and B and enable immediate, effective treatment decisions.
- Early detection - positive results in as few as 5 minutes, with 95% detected within 7 minutes
- Negative results in 13 minutes
- Detects up to 42% more true positives than RADTs
- Room temperature storage
- CLIA waived
- Preferred sample type
- Gives you the confidence to make clinical decisions sooner
- Facilitates effective patient management
- Aids targeted antiviral therapy and Antimicrobial Stewardship
 |
 |
 |
Unique isothermal amplification technology giving you molecular results, faster than ever before
? Improving patient outcomes
Giving you the confidence to make appropriate clinical decisions sooner
? Optimizing operational efficiency
- Facilitating effective patient management
- Enables prompt initiation of infection control measures
- Connected results direct to your network
? Enabling effective Antimicrobial Stewardship
Molecular sensitivity in an actionable timeframe allows the prudent use of antibiotics and antivirals
? A positive impact on your facility
Reliable near-patient testing reduces overall healthcare costs
? Confidence at the point of care
Intuitive and reliable, allowing you to respond quickly and accurately in any setting
How could a rapid molecular result optimize patient care in your facility?
Clinicians often have to make immediate treatment decisions based only on signs and symptoms due to poor access to sensitive, rapid diagnostics test and long turnaround times for laboratory PCR results. However, evidence suggests that clinical judgement alone has sensitivity rates between 29% and 36%. New highly sensitive rapid diagnostic tests for influenza are needed to help guide management in the clinical setting.
Rapid results in time to make a difference
Accurate Performance
